# ARGENICA APPOINTS DR JEFFERY SAVER TO CLINICAL ADVISORY COMMITTEE

**Perth, Australia; 11 JUNE 2022 -** Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, is pleased to announce the appointment of Dr. Jeffery Saver, globally recognised stroke clinician and triallist, to the Company's Clinical Advisory Committee (CAC).

Dr. Saver is Professor and Senior Associate Vice-Chair of Neurology at the University of California at Los Angeles (UCLA) and the Director of the UCLA Comprehensive Stroke Center. Dr. Saver is a fellow of the Stroke Council of the American Heart Association and the American Academy of Neurology. He received both his undergraduate and medical degrees from Harvard University and trained in internal medicine at Brigham and Women's Hospital in Boston and in neurology at the Harvard-Longwood Neurological Training Program. Dr. Saver performed additional subspecialty fellowship training in cognitive neuroscience at the University of Iowa and in cerebrovascular disease at Brown University.

Dr. Saver has an impressive track record in conducting clinical trials and has been the global or site principal investigator for more than 50 clinical trials in stroke. One of the most ambitious and groundbreaking was FAST-MAG, a first-of-its-kind study showing that paramedics can safely give intravenous medication to stroke patients in the ambulance.

Argenica's Chair of the Clinical Advisory Committee, Dr. David Blacker said: "We are absolutely delighted to have Dr Saver join Argenica's Clinical Advisory Committee. He is a highly regarded pioneer of neuroprotection and is the lead author of the revolutionary FAST-MAG study. He will provide invaluable guidance to the Argenica team through the clinical development program."

*This announcement has been approved for release by the Board of Argenica*

For more information please contact: info@argenica.com.au

**ABOUT ARGENICA**

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.